<?xml version='1.0' encoding='utf-8'?>
<document id="23210726"><sentence text="A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin."><entity charOffset="75-85" id="DDI-PubMed.23210726.s1.e0" text="dabigatran" /><entity charOffset="104-118" id="DDI-PubMed.23210726.s1.e1" text="clarithromycin" /><pair ddi="false" e1="DDI-PubMed.23210726.s1.e0" e2="DDI-PubMed.23210726.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23210726.s1.e0" e2="DDI-PubMed.23210726.s1.e1" /></sentence><sentence text="The aim of this study was to develop a PK/PD model to assess drug-drug interactions between dabigatran and P-gp modulators, using the example of clarithromycin, a strong inhibitor of P-gp"><entity charOffset="92-102" id="DDI-PubMed.23210726.s2.e0" text="dabigatran" /><entity charOffset="145-159" id="DDI-PubMed.23210726.s2.e1" text="clarithromycin" /><pair ddi="false" e1="DDI-PubMed.23210726.s2.e0" e2="DDI-PubMed.23210726.s2.e0" /><pair ddi="false" e1="DDI-PubMed.23210726.s2.e0" e2="DDI-PubMed.23210726.s2.e1" /></sentence><sentence text="" /><sentence text="Ten healthy male volunteers were randomized to receive in the first treatment period a single 300 mg dose of dabigatran etexilate (DE) and in the second treatment period 500 mg clarithromycin twice daily during 3 days and then 300 mg DE plus 500 mg clarithromycin on the fourth day, or the same treatments in the reverse sequence"><entity charOffset="109-129" id="DDI-PubMed.23210726.s4.e0" text="dabigatran etexilate" /><entity charOffset="131-133" id="DDI-PubMed.23210726.s4.e1" text="DE" /><entity charOffset="177-191" id="DDI-PubMed.23210726.s4.e2" text="clarithromycin" /><entity charOffset="249-263" id="DDI-PubMed.23210726.s4.e3" text="clarithromycin" /><entity charOffset="234-247" id="DDI-PubMed.23210726.s4.e4" text="DE" /><pair ddi="false" e1="DDI-PubMed.23210726.s4.e0" e2="DDI-PubMed.23210726.s4.e0" /><pair ddi="false" e1="DDI-PubMed.23210726.s4.e0" e2="DDI-PubMed.23210726.s4.e1" /><pair ddi="false" e1="DDI-PubMed.23210726.s4.e0" e2="DDI-PubMed.23210726.s4.e2" /><pair ddi="false" e1="DDI-PubMed.23210726.s4.e0" e2="DDI-PubMed.23210726.s4.e4" /><pair ddi="false" e1="DDI-PubMed.23210726.s4.e0" e2="DDI-PubMed.23210726.s4.e3" /><pair ddi="false" e1="DDI-PubMed.23210726.s4.e1" e2="DDI-PubMed.23210726.s4.e1" /><pair ddi="false" e1="DDI-PubMed.23210726.s4.e1" e2="DDI-PubMed.23210726.s4.e2" /><pair ddi="false" e1="DDI-PubMed.23210726.s4.e1" e2="DDI-PubMed.23210726.s4.e4" /><pair ddi="false" e1="DDI-PubMed.23210726.s4.e1" e2="DDI-PubMed.23210726.s4.e3" /><pair ddi="false" e1="DDI-PubMed.23210726.s4.e2" e2="DDI-PubMed.23210726.s4.e2" /><pair ddi="false" e1="DDI-PubMed.23210726.s4.e2" e2="DDI-PubMed.23210726.s4.e4" /><pair ddi="false" e1="DDI-PubMed.23210726.s4.e2" e2="DDI-PubMed.23210726.s4.e3" /><pair ddi="false" e1="DDI-PubMed.23210726.s4.e4" e2="DDI-PubMed.23210726.s4.e4" /><pair ddi="false" e1="DDI-PubMed.23210726.s4.e4" e2="DDI-PubMed.23210726.s4.e3" /></sentence><sentence text=" Dabigatran plasma concentration and ecarin clotting time (ECT) were measured on 11 blood samples"><entity charOffset="1-11" id="DDI-PubMed.23210726.s5.e0" text="Dabigatran" /></sentence><sentence text=" Models were built using a non-linear mixed effect modelling approach" /><sentence text="" /><sentence text="The best PK model was based on an inverse Gaussian absorption process with two compartments" /><sentence text=" The relationship between dabigatran concentration and ECT was implemented as a linear function"><entity charOffset="26-36" id="DDI-PubMed.23210726.s9.e0" text="dabigatran" /></sentence><sentence text=" No continuous covariate was associated with a significant decrease in the objective function" /><sentence text=" The concomitant administration of clarithromycin induced a significant change only in DE bioavailability, which increased from 6"><entity charOffset="35-49" id="DDI-PubMed.23210726.s11.e0" text="clarithromycin" /><entity charOffset="87-100" id="DDI-PubMed.23210726.s11.e1" text="DE" /><pair ddi="false" e1="DDI-PubMed.23210726.s11.e0" e2="DDI-PubMed.23210726.s11.e0" /><pair ddi="false" e1="DDI-PubMed.23210726.s11.e0" e2="DDI-PubMed.23210726.s11.e1" /></sentence><sentence text="5% to 10" /><sentence text="1% in the presence of clarithromycin"><entity charOffset="22-36" id="DDI-PubMed.23210726.s13.e0" text="clarithromycin" /></sentence><sentence text=" Clarithromycin increased peak concentration and AUC by 60"><entity charOffset="1-15" id="DDI-PubMed.23210726.s14.e0" text="Clarithromycin" /></sentence><sentence text="2% and 49" /><sentence text="1% respectively" /><sentence text="" /><sentence text="The model proposed effectively describes the complex PK of dabigatran and takes into account drug-drug interactions with P-gp activity modulators, such as clarithromycin"><entity charOffset="59-69" id="DDI-PubMed.23210726.s18.e0" text="dabigatran" /><entity charOffset="155-169" id="DDI-PubMed.23210726.s18.e1" text="clarithromycin" /><pair ddi="false" e1="DDI-PubMed.23210726.s18.e0" e2="DDI-PubMed.23210726.s18.e0" /><pair ddi="false" e1="DDI-PubMed.23210726.s18.e0" e2="DDI-PubMed.23210726.s18.e1" /></sentence><sentence text="" /></document>